Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Normethadone is a synthetic opioid analgesic and antitussive agent. It acts primarily as an agonist at central opioid receptors in the medulla to suppress the cough reflex and likely also activates peripheral opioid receptors to inhibit signaling by irritant receptors of the airway. Normethadone is used for the treatment of cough when other less potent treatments have failed and has been marketed in combination with oxilofrine under brand names such as Cophylac. It is significantly more potent than morphine (12–20 times) and has a long duration of action (elimination half-life about 14 days). The drug is classified as an opioid analgesic and antitussive agent[1][2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on normethadone.